HTG Molecular Diagnostics EBIT

HTG Molecular Diagnostics (HTGMQ) currently reports a EBIT of $-20M as of March 2023. That compares with $-18M in the prior-year period — down 11.6% year over year. That is below the Healthcare sector average of $23B. Use the charts on this page to explore HTG Molecular Diagnostics's EBIT history and peer comparisons.

HTG Molecular Diagnostics's EBIT decreased from $-18M to $-20M — a 11.6% year-over-year decrease (period ending March 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

HTG Molecular Diagnostics's EBIT of $-20M is lower than the Healthcare sector average of $23B. That is roughly 100.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

HTG Molecular Diagnostics reported $-20M in EBIT as of March 2023. That compares with $-18M in the prior-year period — down 11.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-20M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $23B. From there, open related valuation or income-statement pages for HTG Molecular Diagnostics, and consider following HTGMQ for alerts when major investors trade the stock.